Fosun Pharma shareholders approve stock option and restricted share plans

Shanghai Fosun Pharmaceutical Group has completed a self-inspection on insider trading related to its 2025 A-share stock option incentive plan, finding no evidence of insider trading or information leakage during the self-inspection period (February 23, 2025, to August 22, 2025). Two individuals traded company shares, but these transactions occurred before any inside information on the incentive plan was formed and were based on public information and personal judgment. The company confirmed it maintains robust information disclosure and insider information management systems.

The company held its 2025 First Extraordinary General Meeting on October 23, 2025, where shareholders approved the 2025 A-share stock option incentive plan and its implementation and assessment management measures. Additionally, the meeting approved the 2025 H-share restricted share unit plan and associated authorization for the board of directors to handle related matters.

Shareholders also approved the allocation of H-share restricted share units to key executives, including Mr. Chen Yuqing (953,500 units), Ms. Guan Xiaohui (686,500 units), Mr. Wen Deming (686,500 units), Mr. Wang Kexin (610,200 units), and Mr. Liu Yi (762,800 units). Other resolutions approved included the renewal of financial services agreements with Shanghai Fosun High-Tech Group Financial Co., Ltd. and product/service supply framework agreements with China National Pharmaceutical Group Corporation.